Follow The Filings

TELA Tela Bio Inc.

Health Care, filed as TELA BIO INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.2%
  • $1.1M

Who owns this now

Largest portfolio weights among holders, up to 0.2% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel 0.21%

Who owns TELA

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.21% Hold 1,441,029 $1.1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TELA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TELA insider trades
  • $4.2M bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Joseph H Capper Director
    Buy
    $89K 75,000 shares at $1.18 +72% to stake
    Traded Sep 16–17 Filed Sep 18
    ↗
  2. Joseph H Capper Director
    Buy
    $78K 75,000 shares at $1.05 +252% to stake
    Traded Sep 14–15 Filed Sep 16
    ↗
  3. Heather C Getz CEO
    Buy
    $8,311 12,500 shares at $0.6600 +2.4% to stake
    Traded Aug 17 Filed Aug 19
    ↗
  4. Heather C Getz CEO
    Buy
    $10K 15,000 shares at $0.7000 +3% to stake
    Traded Aug 14 Filed Aug 17
    ↗
  5. Ew Healthcare Partners Fund 2, L.P. 10% owner, +3 joint filers
    Buy
    $4M 3,604,000 shares at $1.11 +88% to stake
    Traded Nov 17, 2025 Filed Nov 17, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 21 stock grants and 12 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 5.07 Filing Doc
8-K 8.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 1.01 Filing Doc
8-K 3.01 Filing Doc
DEF 14A Filing Doc
8-K 2.05,5.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K/A 5.02 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13D — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
DEF 14A Filing Doc
8-K 2.02,5.02 Filing Doc
DEFA14A Filing Doc
10-K Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 3.01 Filing Doc

Source: SEC EDGAR submissions, updated 13 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $58.45M $69.3M $80.28M
Gross profit $40.11M $46.49M $54.34M
Gross margin * 68.6% 67.1% 67.7%
Net income -$46.66M -$37.84M -$38.83M
Net margin * -79.8% -54.6% -48.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $71.73M $78.07M $75.58M
Total non-current assets * $6.32M $8.5M $5.84M
Total assets $78.05M $86.57M $81.42M
Total current liabilities $16.97M $15.6M $17.98M
Total non-current liabilities * $42.2M $42.51M $57.13M
Total equity $18.88M $28.46M $6.31M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$40.86M -$41.6M -$28.22M
Cash from investing -$0.599M $4.45M $0.846M
Cash from financing $46.27M $43.06M $25.75M
Net change in cash $4.98M $5.94M -$1.84M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.